Skip to content
Screener

ARS Pharmaceuticals, Inc. SPRY Q1 2026 earnings

Reported May 15, 2026 · Before market open

Revenue$22.7MBeat by $481.0K
EPS-$0.61Miss by $0.08
Revenue estimate$22.2M
EPS estimate-$0.53

Next report

Nov 9, 2026 (in 2 months)
Revenue estimate$42.8M
EPS estimate-$0.33

Financials

Q1 2026

Income statement

See full
Revenue$22.7M+184%
Operating income-$60.1M-61.8%
Net income-$60.6M-78.6%
EPS (diluted)-$0.61-74.3%

Balance sheet

See full
Cash & equivalents$24.3M-39.0%
Total debt$96.5M+132,122%
Total equity$61.3M-73.2%
Total assets$287.6M-12.1%

Cash flow

See full
Operating cash flow-$44.9M-10.3%
CapEx--100%
Free cash flow-$44.9M-10.1%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$797.36M-35.4%
Enterprise value$869.56M-27.2%
P/S8.1×-4.7×

Profitability

See full
Operating margin-204.5%—
Net margin-200%-219pp
FCF margin-177.1%-206pp

Returns & leverage

See full
Return on equity-136.4%-144pp
Debt / equity1.6×+1.6×
Current ratio4.9×-6.1×

Segments

By geography

See full
Non Us$2.5M—

FAQ

When did ARS Pharmaceuticals, Inc. report Q1 2026 earnings?
ARS Pharmaceuticals, Inc. (SPRY) reported Q1 2026 earnings on May 15, 2026 before market open.
What were ARS Pharmaceuticals, Inc.'s Q1 2026 revenue and EPS?
ARS Pharmaceuticals, Inc. reported revenue of $22.7M and eps of $-0.61 for Q1 2026.
Did ARS Pharmaceuticals, Inc. beat estimates in Q1 2026?
Revenue beat the consensus estimate of $22.2M by $481.0K. EPS missed the consensus estimate of $-0.53 by $0.08.
How did ARS Pharmaceuticals, Inc.'s Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 184.5% from $8.0M a year earlier and eps declined 74.3% from $-0.35.
Where can I find ARS Pharmaceuticals, Inc.'s Q1 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-220671) and the 10-Q periodic report (0001193125-26-225142) directly on SEC EDGAR. The filing index links above go to sec.gov.